111in-dota-h11b6
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 18, 2019 (NCT04116164)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04116164 | Early Phase 1 (Phase 1) | Sep 18, 2019 | Invicro, Janssen Pharmaceutica NV, Memorial Sloan-Kettering Cancer Center, Tomopath Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Invicro | For profit | 1 | 0 | 1 | 2019 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Tomopath Inc. | For profit | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1